Can We Lower the Burden of Antimicrobial Resistance (AMR) in Heavily Immunocompromised Patients? A Narrative Review and Call to Action

We are pleased to announce the release of a significant new narrative review entitled “Can We Lower the Burden of Antimicrobial Resistance (AMR) in Heavily Immunocompromised Patients? A Narrative Review and Call to Action”, published online on 7 August 2025.

This comprehensive review spotlights the critical challenge of antimicrobial resistance (AMR) among patients with weakened immune systems—such as those undergoing cancer treatment or organ transplants. Key insights include:

• Severe risks to treatment efficacy: AMR threatens to undermine modern therapies, risking delays in cancer treatment, prolonged hospital stays, higher mortality, and reduced patient quality of life.

• Economic and systemic strain: The financial burden of AMR is substantial—limiting the efficacy of costly novel therapies and increasing healthcare costs.

• Urgent need for coordinated action: The review calls for improved infection control, faster diagnostics, robust antimicrobial stewardship, and education initiatives targeting both healthcare providers and patients.

• Holistic benefits: Strengthening AMR management could ensure safer access to breakthrough treatments and deliver significant cost savings to healthcare systems.

This article reflects the concerted effort of a multi-national team of experts led by Matteo Bassetti and collaborators from leading institutions across Europe.

Publication Details:

• Title: Can We Lower the Burden of Antimicrobial Resistance (AMR) in Heavily Immunocompromised Patients? A Narrative Review and Call to Action

• Journal: Infectious Diseases and Therapy

• Publication Date: 7 August 2025

• DOI: 10.1007/s40121-025-01204-4

• Read more: https://pubmed.ncbi.nlm.nih.gov/40772992/